2023. Phase 2 confirmatory study of cemiplimab (350 mg IV Q3W) in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Study 1540 Group 6. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s175. DOI:https://doi.org/10.25251/skin.7.supp.175.